Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics
29 April 2024 - 5:45PM
Business Wire
Cellvizio utilization continues to expand
globally in established and emerging clinical indications
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)
(Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe
and needle-based confocal laser endomicroscopy (p/nCLE) platform,
today announced the opening of a French Center of Excellence for
the use of Cellvizio in lung cancer diagnostics. The Cellvizio
procedure is now performed preoperatively by Prof. Stéphane Renaud,
MD, PhD, a leading thoracic surgeon at the University Hospital
(CHRU) in Nancy, France. This initiative is part of a global
strategic expansion plan to establish Centers of Excellence in
established and emerging clinical indications in several
countries.
The rise in lung cancer screening coupled with the increased use
of chest-computed tomography (CT) has generated a surge in the
detection of suspected malignant lung lesions globally, increasing
the need for more effective and efficient diagnostic methods. Given
that over 80% of these incidental lesions develop in the peripheral
bronchi, they pose a challenge to conventional bronchoscopy due to
their difficult visualization and accessibility.
Combined with endobronchial navigation, Cellvizio improves
bronchoscopy and allows simple, minimally invasive access to all
areas of the lung, revealing the cellular architecture of tissues
in real time. This direct visualization is a game-changer, because
it enables instant guidance to be given, even for small lesions,
without waiting for rapid cytology results, which are of very low
diagnostic quality. This innovation not only reduces the length of
procedures, but also improves diagnostic accuracy by enabling
precise targeting of lesions and of biopsies, while providing
greater safety for patients.
"In the field of cancer diagnosis, the precision of biopsy
locations is essential. Traditional methods risk sampling from
necrotic or merely inflammatory sites, leading to potentially
misleading, false-negative results. Cellvizio's real-time visual
inspection empowers us to target biopsies more accurately, focusing
on areas that visually exhibit suspicious characteristics. This
strategic approach significantly mitigates the risk of false
negatives, ensuring a higher degree of diagnostic confidence”
commented Professor Stéphane Renaud, MD, PhD, Department of
Thoracic Surgery, Nancy Regional University Hospital,
France.
"With the upcoming programs of lung cancer screening in Europe,
there is a planned exponential growth of bronchoscopic examinations
of patients with difficult to reach peripheral nodules that can
lead to false negatives, additional unnecessary procedures and
costs. Cellvizio has been proven to be a key addition to
bronchoscopy in order to improve the physician’s ability to place
biopsy tools precisely in the lesions and improve the overall
diagnostic yield said Sacha Loiseau, Ph.D., Founder, Chairman
and Chief Executive Officer of Mauna Kea Technologies. “We are
very excited to have the University Hospital in Nancy serve as our
Center of Excellence for Cellvizio in lung cancer diagnostics in
France, another significant step forward in the scaling of the use
of Cellvizio in the ever-expanding field of lung cancer diagnosis
and treatment.”
***
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio® platform is used globally across a
wide range of medical specialties and is making a transformative
change in the way physicians diagnose and treat patients. For more
information, visit www.maunakeatech.com.
Disclaimer This press release contains forward-looking
statements about Mauna Kea Technologies and its business. All
statements other than statements of historical fact included in
this press release, including, but not limited to, statements
regarding Mauna Kea Technologies' financial condition, business,
strategies, plans and objectives for future operations are
forward-looking statements. Mauna Kea Technologies believes that
these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the
expectations expressed in these forward-looking statements will be
achieved. These forward-looking statements are subject to numerous
risks and uncertainties, including those described in Chapter 3 of
Mauna Kea Technologies' 2022 Universal Registration Document filed
with the Autorité des marchés financiers (AMF) on June 28, 2023
under number D-23-0545, which is available on the Company's website
(www.maunakeatech.fr), as well as the risks associated with changes
in economic conditions, financial markets and the markets in which
Mauna Kea Technologies operates. The forward-looking statements
contained in this press release are also subject to risks that are
unknown to Mauna Kea Technologies or that Mauna Kea Technologies
does not currently consider material. The occurrence of some or all
of these risks could cause the actual results, financial condition,
performance or achievements of Mauna Kea Technologies to differ
materially from those expressed in the forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or subscribe for, or the solicitation
of an order to buy or subscribe for, shares of Mauna Kea
Technologies in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. The
distribution of this press release may be restricted in certain
jurisdictions by local law. Persons into whose possession this
document comes are required to comply with all local regulations
applicable to this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429852256/en/
Mauna Kea Technologies investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas
Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024